At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 46 enrolled
Drug / intervention
adalimumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis
In Brief
A Phase 3 clinical trial evaluating adalimumab and placebo for adalimumab for Enthesitis Related Arthritis (ERA). Completed, enrolled 46 participants.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of adalimumab given subcutaneously every other week (eow) as compared to placebo in pediatric subjects with Enthesitis Related Arthritis (ERA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnthesitis Related Arthritis (ERA)
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2010
Enrollment StartSep 2010
Primary CompletionNov 2012
Study CompletionDec 2015
TodayJul 2026
First PostedJul 21, 2010
Enrollment StartSep 1, 2010
Primary CompletionNov 1, 2012
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 15.9 years ago
Interventions
adalimumabbiological
Adalimumab solution for subcutaneous injection.
placebo for adalimumabbiological
Placebo for adalimumab solution for subcutaneous injection.